Is there is a difference between incremental cost-effectiveness ratios (ICERs) in oncology calculated by the Institute for Clinical and Economic Review (ICER) in the US and the National Institute for Health and Care Excellence (NICE) in the UK, and if so, are any differences are solely driven by drug costs.

Read our findings here ICERS are not all the same. How cost-effectiveness estimates differ between the UK and US